Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
about
The Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityPharmacogenetic testing: Current Evidence of Clinical Utility.Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use.HLA and pharmacogenetics of drug hypersensitivity.A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Economic Evaluations of Pharmacogenetic Approaches in Infectious Diseases: A Review of Current Approaches and Evaluation of Critical Aspects Affecting their Quality.
P2860
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Cost impact of prospective HLA ...... ose combination use in Germany
@en
Cost impact of prospective HLA ...... ose combination use in Germany
@nl
type
label
Cost impact of prospective HLA ...... ose combination use in Germany
@en
Cost impact of prospective HLA ...... ose combination use in Germany
@nl
prefLabel
Cost impact of prospective HLA ...... ose combination use in Germany
@en
Cost impact of prospective HLA ...... ose combination use in Germany
@nl
P2093
P2860
P1476
Cost impact of prospective HLA ...... ose combination use in Germany
@en
P2093
D Gorriahn
J R Bogner
M Baudewig
M Blankenburg
M C Mueller
P2860
P2888
P304
P356
10.1186/2047-783X-15-4-145
P407
P577
2010-04-01T00:00:00Z
P6179
1012645137